Schizophrenia/Psychosis

Explore the complex role of dopamine in schizophrenia, its impact on symptoms, and potential therapeutic advancements.

Early intervention in schizophrenia enhances recovery, reduces symptoms, and improves quality of life through coordinated specialty care programs across the US.

In this Special Report, explore groundbreaking insights on schizophrenia treatment, early intervention strategies, and the impact of childhood trauma on psychosis.

Antipsychotic plasma levels play a critical role of in treatment decisions. Learn more in this conversation from the 2025 APA Annual Meeting.

Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.

Angelo Chaia, MD, explores the impact of long-acting injectables on patients with severe mental illness and substance use disorders at the 2025 APA Annual Meeting.

Amir Meftah, MD, discusses the possibility of GLP-1s for addressing metabolic issues associated with antipsychotics.

Newron Pharmaceuticals launches pivotal ENIGMA-TRS trials for evenamide, targeting treatment-resistant schizophrenia with promising efficacy and safety outcomes.

Research reveals that IV haloperidol and ziprasidone are safe for treating delirium in patients that are critically ill, showing minimal impact on QTc intervals.

Learn more about the latest advancements in schizophrenia treatment and the ongoing battle against stigma during Mental Health Awareness Month.

Check out the pipeline updates from April!

Peter J. Weiden, MD, discusses the latest Cobenfy data and implications for schizophrenia treatment.

Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the primary endpoint of the phase 3 ARISE trial, or a statistically significant difference compared with placebo with an atypical antipsychotic.

How can psychiatric professionals and pharmacists best work together to improve patient care? One pharmacist shares his thoughts.

Different medications for different domains: new treatments are changing the way schizophrenia is managed.

Take a look at the differentiation between prodrome and attenuated psychosis, along with cognitive impairment associated with schizophrenia.

Here's what patients should know about Cobenfy for the treatment of schizophrenia.

Without the scaffolding of the REMS requirement for clozapine, how can you best utilize this treatment?

How can you best transition patients to Cobenfy if they are already taking an antipsychotic medication?

Peripartum psychosis is considered a psychiatric emergency. Here is how an interdisciplinary team can provide the best care.

Adherence, switching, and quality of life are top concerns in BDI, and schizophrenia.

How does John Kane, MD, address issues of cognition in schizophrenia?

SPG302, a regenerative treatment for schizophrenia, could reset the clock on the brain.

John Kane, MD, believes the removal of the REMS requirement for clozapine could help improve utilization for this "grossly underutilized" drug.

Treatments that target negative and cognitive symptoms of schizophrenia could put patients in better control of their life.